Greenberg Traurig has advised Samsung Electronics on its USD175 million investment in an upsized series E financing round for Element Biosciences, making the South Korean giant the company’s largest shareholder.
Element Biosciences also received funding from other investors, although the total amount was not disclosed.
The Greenberg Traurig team was led by shareholder Wayne Elowe, co-chair of the firm’s global life sciences and medical technology group and co-chair of the corporate practice in Atlanta.
Shareholders Kyle Oh and Brian Petrequin were also part of the corporate team, alongside associates Brian Landau, William Grossenbacher, Mary Kathryn Cicchillo, Sophia Korn and Alex Kwon.
The corporate team was supported by attorneys across multiple practice areas, including IP and technology, health care and FDA, labour and employment, international trade, antitrust litigation and competition regulation, real estate, and data privacy and cybersecurity.
Proceeds from the series E financing will be used to support the commercialisation and adoption of Element’s expanding genomic and multiomic solutions, as well as to grow its global footprint and advance its product roadmap.
The transaction’s closing remains subject to regulatory approvals.
